In a deal set to boost its urology offerings, Boston Scientific said it will acquire NxThera for about $406 million.
The New Jersey Superior Court’s appellate division refused to reinstate a hernia mesh product liability lawsuit against Becton Dickinson's C.R. Bard because expert witnesses couldn't prove the design of the product was defective or that significant negligence occurred.
Endologix reported positive results from ENCORE, a pooled analysis of several prospective studies evaluating polymer endovascular aneurysm repair using the company's Ovation abdominal stent graft systems.
Colibri has treated the first two patients in a feasibility study and cites Edwards Lifesciences as its main competition in the TAVR market.
Amazon has reportedly hooked a former FDA officer for its new healthcare business, but we still don't know much about this secretive new venture.
Partnership aims to connect as many devices as possible, even a bare syringe, to help improve patient adherence.
Johnson & Johnson continues its exodus from the diabetes market and has received a $2.1B offer from Platinum Equity to acquire LifeScan.
A new study has confirmed the accuracy of the Xpresys Lung 2 test developed by Integrated Diagnostics.
Corindus Vascular tops revenue expectations for the fourth quarter of 2017 and gears up for tele-stenting trial with Mayo Clinic.
Texas A&M is launching a new engineering-based medical degree program in partnership with Houston Methodist Hospital that will educate a new kind of doctor with an engineering mindset.
The SEC charged Theranos, its founder and CEO Elizabeth Holmes, and its former president Ramesh "Sunny" Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about the company's technology, business, and financial performance.
Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
FDA gave the company the green light to end a trial of its LAP-BAND System early, saving the company more than $5 million.
Medtronic continued to strengthen its TAVR story with 5-year-data recently presented at ACC18. The company is battling it out with Edwards in the U.S. market, while Boston Scientific seeks to find footing after delaying commercialization of the Lotus Edge valve.
After suffering a spinal cord injury eight years ago, doctors told Paul Campbell there was only a 3% chance he would ever walk again, Campbell said after walking across a room at SXSW with the assistance of the Phoenix exoskeleton from suitX.